TIVC Form 4/A Corrects Vesting for 45,000-Share Option to COO
Rhea-AI Filing Summary
Tivic Health Systems insider amendment: Michael K. Handley, Chief Operating Officer and director, amended a Form 4 to correct the vesting schedule for an employee stock option granted on 08/06/2025. The option covers 45,000 shares of common stock with an exercise price of $3.32 per share and an expiration date of 08/05/2035. The corrected vesting is 25% on the first anniversary of the grant and the remaining 75% in twelve equal quarterly installments measured from the first anniversary, so that the option is fully vested by the fourth anniversary. The amendment was signed by an attorney-in-fact on 08/22/2025.
Positive
- Corrected reporting improves accuracy of Section 16 disclosures
- Clear vesting schedule specified: 25% after one year, remaining 75% over twelve quarterly installments
Negative
- No information in this filing on potential accounting impact or dilution from the option
- Administrative error required an amendment, indicating prior filing inaccuracy
Insights
TL;DR: Amendment clarifies vesting for a 45,000-share option to the COO; transaction is routine disclosure without direct financial results.
The filing is an administrative correction to the originally reported vesting schedule for an employee stock option granted to Michael K. Handley. Key facts: the option covers 45,000 common shares at a $3.32 exercise price, vests 25% after one year with the remainder in twelve equal quarterly installments, and expires 08/05/2035. This is a disclosure and governance matter ensuring accurate Section 16 reporting; it does not itself report cash proceeds or equity transfers. Impact on outstanding shares or compensation expense is not disclosed in this Form 4/A and cannot be determined from the filing alone.
TL;DR: The amendment corrects an administrative error; the corrected schedule aligns with a typical multi-year vesting structure.
This Form 4/A explicitly states the corrected vesting cadence: 25% at the one-year anniversary and the remaining 75% over twelve equal quarterly installments, completing vesting at year four. The filing identifies the reporting person as the COO and a director and confirms the amendment was executed by an attorney-in-fact on 08/22/2025. No additional terms, cash payments, or equity issuance quantities beyond the 45,000-option grant are included. The disclosure improves transparency but contains no new material operational or financial information.